1. Dr. Horst Hemmerle Eli Lilly & Company Director Lead Generation Technologies: Responsible for: Compound Collection Enrichment Strategy Screening Strategies – Target families DCRT Technologies /Automation Chemoinformatics/Chemogenomics

2. Disease mechanism FAS VEGF Cellular mechanism Molecular mechanism Prostate Cancer Angiogenesis Annotated chemical diversity compounds Targets Apoptosis Solving Complex Issues Informatcis platforms allow integration and creation of knowledge Analysis – Predictions - Simulations

3. Library Deliverables Dynamic Library compoundsdata Iterative Screen Panels KinasesGPCRs NHRsIon Channels ProteasesLipases Transporters Ideal Drug Properties Structural Novelty Kinases GPCRs NHRs MTS of selected cassettes for Drug Discovery efforts Selected sets for Target of Interest evaluation Validation Tools (Hits,Fragments) Ligands to Explore Polypharm Hits/Leads/Back-up Scaffolds Active Compounds and Information